Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Published 16/04/2024, 07:15
© Reuters. Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Johnson & Johnson (NYSE: JNJ) is set to release earnings results for its first quarter before the opening bell on April 16, 2024.

Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.64 per share, up from $2.41 per share in the year-ago period. Johnson & Johnson is projected to report quarterly revenue of $21.40 billion, compared to $24.75 billion in the year-earlier quarter, according to data from Benzinga Pro.

Rallybio recently announced a collaboration with Johnson & Johnson to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Johnson & Johnson shares rose 0.1% to close at $147.59 on Monday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

  • Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $215 on April 15, 2024. This analyst has an accuracy rate of 62%.
  • Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $170 to $169 on Jan. 24, 2024. This analyst has an accuracy rate of 69%.
  • Raymond James analyst Jayson Bedford maintained an Outperform rating and raised the price target from $172 to $175 on Jan. 3, 2024. This analyst has an accuracy rate of 68%.
  • Wells Fargo analyst Larry Biegelsen downgraded the stock from Overweight to Equal-Weight and cut the price target from $170 to $163 on Dec. 13, 2023. This analyst has an accuracy rate of 73%.
  • UBS analyst Danielle Antalffy upgraded the stock from Neutral to Buy with a price target of $180 on Dec. 1, 2023. This analyst has an accuracy rate of 62%.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Read This Next: Brightcove And 1 Other Penny Stock Insiders Are Buying

Latest Ratings for JNJ

Jan 2022Raymond JamesMaintainsOutperform
Jan 2022Morgan StanleyMaintainsEqual-Weight
Dec 2021Goldman SachsInitiates Coverage OnNeutral

View the Latest Analyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.